STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound
Top of the morning to you. And a fine one it is. Lots of sunshine…
Category: Pharmalot
STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns
In its latest bid to police the pharmaceutical industry, the U.S. Federal Trade Commission sought…
STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The prices of 8 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2022, report finds
During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical…
STAT+: Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year
Amid fears of superbugs, the sale of medically important antibiotics given to food-producing livestock rose…
STAT+: Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of unaffordable medicines
In a win for Vertex Pharmaceuticals, a Colorado state board voted not to place the…
STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Biden proposal targeting pharma patents spurs industry fears and consumer doubts
Will this be a half a loaf? After months of deliberation, the Biden administration on…
STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer…
Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents
With 10 days to go, only one company has responded to a demand by the…
STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues
In a victory for the pharmaceutical industry, a U.S. judge ruled that Minnesota must temporarily…
STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds
In the wake of the Covid-19 pandemic, the Food and Drug Administration inspected far fewer…
STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: U.S. Supreme Court to review controversial Purdue Pharma bankruptcy settlement
After weeks of anticipation, the U.S. Supreme Court on Monday will hear arguments to decide…
STAT+: Texas AG accuses Pfizer of ‘intentionally’ overstating Covid-19 vaccine effectiveness
The Texas attorney general has filed a lawsuit accusing Pfizer of “unlawfully” and “intentionally” misrepresenting…
STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official attacks Bristol over Medicare price talks
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough
Vertex Pharmaceuticals is being accused by a group of advocates and physicians of refusing to…
STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs
In response to strained budgets, a growing number of state and local governments across the…
STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds
Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year…
STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market
Good morning, everyone, and nice to see you again after an extended break on this…
STAT+: Sales of antibiotics for food-producing animals dropped by more than half in Europe over the past decade
Amid concerns over the use of medically important antibiotics given to food-producing livestock, sales of…
Pharmalittle: European patent agency invalidates a Moderna mRNA patent; pharma ally Eshoo plans to retire
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in…
STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup
Hello, everyone. Damian Garde here, filling in for Ed Silverman on what is an abbreviated…
STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs
Good morning and welcome to Thanksgiving week! STAT reporter Andrew Joseph here filling in for…
STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs
And so, another working week will soon draw to a close Not a moment too…
STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant
Dr. Reddy’s Laboratories, one of the world’s largest generic drugmakers, was cited by the U.S….
STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds
The patents on medicines and devices approved by the U.S. Food and Drug Administration were…
STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Michigan bill that would pare back pharma liability shied law moves closer to enactment
A one-of-a-kind law in Michigan that prevents the state government and residents from suing pharmaceutical…
STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings
Making good on a recent threat, the U.S. Federal Trade Commission is challenging more than…
STAT+: FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs
After years of trying, the U.S. Food and Drug Administration is again seeking to withdraw…
STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value…
STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Health plan formularies lowered barriers to fair access to some drugs, analysis finds
Most of the formularies run by some of the largest health plans in the U.S….
STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Nostrum Laboratories and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates
A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising…